Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib and Myelofibrosis Outcome

Expert Rev Hematol; ePub 2016 Dec 16; Massaro, et al

Publish date:

Ruxolitinib modifies the natural outcome of myelofibrosis in both primary and secondary diseases, according to a recent review of randomized trials and an analysis of an independent series of patients. Among the findings:

  • There is a survival advantage with ruxolitinib vs placebo or best available therapy.
  • JAK2 allele burden was reduced during treatment and about half of patients achieved improvement or stabilization of fibrosis; several pathways are involved.

Citation:

Massaro F, Molica M, Breccia M. How ruxolitinib modified the outcome in myelofibrosis: Focus on overall survival, allele burden reduction and fibrosis changes. [Published online ahead of print December 16, 2016]. Expert Rev Hematol. doi:10.1080/17474086.2017.1273766.

This Week's Must Reads